Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use

Inventors

Pettine, Kenneth Allen • MOSELEY, Timothy Alexander

Assignees

Direct Biologics LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12213995-B2

Patent

Publication Date

2025-02-04

Expiration Date


Abstract

Disclosed are compositions comprising a MSC secretome preparation and cannabinoids and methods of the use of said compositions for the treatment of inflammatory conditions.

Core Innovation

The invention relates to therapeutic compositions and methods for treating inflammatory conditions by combining an MSC secretome preparation with a cannabinoid. The MSC secretome preparation includes MSC growth factors, MSC extracellular vesicles, MSC exosomes, and/or MSC extracts, and the cannabinoid is administered together with the MSC-derived components to address inflammation-related diseases.

A defining aspect is that the MSC secretome preparation is obtained from human bone-marrow MSCs cultured under conditions comprising about 0.1% to about 5% oxygen and an acidic pH of 6.2 to 6.9. These culture conditions generate an MSC secretome preparation that is then used in combination with a cannabinoid for therapeutic administration to a subject.

The disclosed rationale describes immune modulation achieved through the combination of MSC-derived secretome components and cannabinoid activity. The document characterizes cannabinoid receptor immunoregulation and shifts in immune pathways, including TH1/TH2 and M1/M2 macrophage phenotypes, with reference to inflammatory mediators and EV-associated proteins and miRNAs implicated in reducing pro-inflammatory mediators such as TNF-α and IL-6.

Claims Coverage

The partial content includes three independent claims covering a composition that combines an MSC secretome preparation and a cannabinoid and methods of treating inflammatory or inflammation-related disorders by culturing bone-marrow MSCs under defined hypoxic and acidic conditions and administering the resulting secretome together with a cannabinoid. The independent claims share the core pairing of an MSC secretome preparation with a cannabinoid and specify how the secretome is generated and/or administered.

MSC secretome preparation plus cannabinoid composition from hypoxic/acidic human bone-marrow MSCs

A composition comprising an MSC secretome preparation comprising MSC growth factors, MSC extracellular vesicles, MSC exosomes, and/or MSC extracts, and a cannabinoid, wherein the MSC growth factors and/or MSC extracellular vesicles and/or MSC exosomes and/or MSC extracts are obtained from human bone-marrow MSCs cultured under conditions comprising about 0.1% to about 5% oxygen and an acidic pH of 6.2 to 6.9.

Treating inflammatory/autoimmune/autoinflammatory/metabolic disorders by generating secretome under hypoxic/acidic conditions and administering with a cannabinoid

A method of treating an inflammatory condition, an autoimmune disease, an autoinflammatory disease, or metabolic disorder in a subject, the method comprising culturing bone-marrow mesenchymal stem cells (MSCs) under conditions comprising about 0.1% to about 5% oxygen and an acidic pH of 6.2 to 6.9 to generate a mesenchymal stem cell (MSC) secretome preparation, and administering to the subject a therapeutically effective amount of the MSC secretome preparation and a cannabinoid.

Treating inflammation by generating secretome under hypoxic/acidic conditions and administering with a cannabinoid

A method of treating inflammation in a subject, the method comprising culturing bone-marrow mesenchymal stem cells (MSCs) under conditions comprising about 0.1% to about 5% oxygen and an acidic pH of 6.2 to 6.9 to generate a mesenchymal stem cell (MSC) secretome preparation and administering to the subject a therapeutically effective amount of the MSC secretome preparation and a cannabinoid.

Across the independent claims, the main inventive coverage centers on producing an MSC secretome preparation from human bone-marrow MSCs cultured under defined hypoxic and acidic conditions, and using that secretome in combination with a cannabinoid for treating inflammation or inflammation-related disorders in a subject.

Stated Advantages

Documented Applications

No documented applications found

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.